Regimen | Study type | Accrual | Major subtype | Median prior therapy | Efficacy | Major AEs | Abstract number | References |
---|---|---|---|---|---|---|---|---|
Novel agent + SCT vs. Chemotherapy + SCT vs. Novel agent vs. Chemotherapy | Retrospective | 184 | AITL (28.3%), PTCL-NOS (21.2%), ATLL (8.5%), and ALCL (13%) | N/A | mEFS 16.0 m vs. 15.0 m vs.3.9 m vs. 4.1 m, mOS 70.7 m vs. not reached vs. 23.3 m vs. 16.7 m | N/A | 1698 | [11] |
Lenalidomide maintenance after salvage therapy | Phase II | 58 | AITL (39.7%), PTCL-NOS (25.9%) | N/A | 1-y PFS 49%, mOS 34.1 m | Hematologic toxicities: Neutropenia, Thrombocytopenia; Non-hematologic toxicities: Skin rash (40%), Nausea (35%), Diarrhea (20%) | 3073 | [12] |
Chidamide + Azacitidine | Phase I | 19 | AITL (57.9%), PTCL-NOS (42.1%) | 2 | ORR 56.25%, DCR 75%, mPFS 6.45 m, mOS 17.5 m | Pain at the injection site (75.0%), Neutropenia (56.3%), Erythema at the injection site (50.0%), Nausea (43.8%), Thrombocytopenia (37.5%), Feeble (37.5%), Anemia (31.3%), Diarrhea (31.3%), Neutropenia with fever (25.0%) | 3076 | [13] |
Chidamide + Parsaclisib | Phase Ib/II | 11 | N/A | 2 | CR 55.6% | Neutropenia (36.4%), Leukopenia (9.1%), Elevation of ALT/AST (9.1%), Diarrhea (9.1%) | 3075 | [14] |